Sulfonylurea Receptor 1 in Central Nervous System Injury : An Updated Review
Jha, Ruchira M. (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Rani, Anupama (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Desai, Shashvat M. (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Raikwar, Sudhanshu (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Mihaljevic, Sandra (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Munoz-Casabella, Amanda (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Kochanek, Patrick M. (University of Pittsburgh)
Catapano, Joshua (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Winkler, Ethan (Barrow Neurological Institute (Phoenix, Estats Units d'Amèrica))
Citerio, Giuseppe (San Gerardo Hospital (Monza, Itàlia))
Hemphill, J. Claude (University of California, San Francisco)
Kimberly, W. Taylor (Massachusetts General Hospital (Boston, Estats Units d'Amèrica))
Narayan, Raj (North Shore University Hospital (Manhasset, Estats Units d'Amèrica))
Sahuquillo Barris, Juan (Hospital Universitari Vall d'Hebron)
Sheth, Kevin N. (Yale University (New Haven, Estats Units d'Amèrica))
Simard, J. Marc (University of Maryland School of Medicine (Baltimore, Estats Units d'Amèrica))
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Sulfonylurea receptor 1 (SUR1) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) protein superfamily, encoded by Abcc8, and is recognized as a key mediator of central nervous system (CNS) cellular swelling via the transient receptor potential melastatin 4 (TRPM4) channel. Discovered approximately 20 years ago, this channel is normally absent in the CNS but is transcriptionally upregulated after CNS injury. A comprehensive review on the pathophysiology and role of SUR1 in the CNS was published in 2012. Since then, the breadth and depth of understanding of the involvement of this channel in secondary injury has undergone exponential growth: SUR1-TRPM4 inhibition has been shown to decrease cerebral edema and hemorrhage progression in multiple preclinical models as well as in early clinical studies across a range of CNS diseases including ischemic stroke, traumatic brain injury, cardiac arrest, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, multiple sclerosis, encephalitis, neuromalignancies, pain, liver failure, status epilepticus, retinopathies and HIV-associated neurocognitive disorder. Given these substantial developments, combined with the timeliness of ongoing clinical trials of SUR1 inhibition, now, another decade later, we review advances pertaining to SUR1-TRPM4 pathobiology in this spectrum of CNS disease-providing an overview of the journey from patch-clamp experiments to phase III trials.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	SUR 1 ; TRPM4 ; Cellular swelling ; Clinical trials ; Edema ; Stroke ; Sulfonylurea receptor ; Traumatic brain injury
Published in:	International journal of molecular sciences, Vol. 22 (november 2021) , ISSN 1422-0067

DOI: 10.3390/ijms222111899
PMID: 34769328

62 p, 26.0 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles